FDA Follow-On Biologics Guidance Will Follow Public Workshop, Agency Tells Senate Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
A public scientific workshop is planned for late summer; timing or content of a guidance cannot be predicted until after the meeting, Acting Commissioner Crawford tells Senate Judiciary Committee. Sen. Schumer expresses concern that progress towards "generic" biologics is "slowing."
You may also be interested in...
FDA Follow-On Biologics Public Meeting Slated For Early 2005
Projected timing of the meeting suggests that release of a draft guidance will not occur until at least a year after FDA’s original projected timeframe of spring 2004.
FDA Follow-On Biologics Public Meeting Slated For Early 2005
Projected timing of the meeting suggests that release of a draft guidance will not occur until at least a year after FDA’s original projected timeframe of spring 2004.
Barr's Generic Biologics Strategy Includes Outsourcing Manufacturing
The value of generic biologics will not come from manufacturing but rather from "navigating the regulatory and legal arena," CEO Downey says. Barr plans to detail its business plan by next June.